<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Genflow Biosciences Plc — News on 6ix</title>
<link>https://6ix.com/company/genflow-biosciences-plc</link>
<description>Latest news and press releases for Genflow Biosciences Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/genflow-biosciences-plc" rel="self" type="application/rss+xml" />
<item>
<title>Expansion of Confidentiality Agreements</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/expansion-of-confidentiality-agreements</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/expansion-of-confidentiality-agreements</guid>
<pubDate>Tue, 28 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has expanded its confidential agreements with Tier-1 animal health companies to include additional parties for the review of data from its canine SIRT6 cent gene therapy program, building on positive preliminary interim results reported in February 2026. These new agreements, alongside existing ones, indicate a growing third-party evaluation of the company's technology and data, though these interactions remain exploratory. The company is encouraged by these discussions a</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Strategic Technology Collaboration</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-strategic-technology-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-strategic-technology-collaboration</guid>
<pubDate>Mon, 20 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Enters Strategic Technology Collaboration with Acuitas Therapeutics - Fully Funded, Non-Dilutive Access to World-Class LNP Delivery Platform LONDON, UK / ACCESS Newswire / April 20, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ...</description>
</item>
<item>
<title>International Patent Publication</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/international-patent-publication</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/international-patent-publication</guid>
<pubDate>Mon, 13 Apr 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has announced the international publication of its Patent Cooperation Treaty application, WO 2026/062177 A1, which expands protection for its SIRT6-based muscular disease program, specifically targeting frailty syndrome and sarcopenia. This publication broadens the potential protection of Genflow's SIRT6 platform beyond longevity and metabolic applications, strengthening its intellectual property estate and supporting future development and partnering opportunities in mul</description>
</item>
<item>
<title>Update on the Dog Study</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/update-on-the-dog-study</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/update-on-the-dog-study</guid>
<pubDate>Wed, 08 Apr 2026 07:55:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced sustained positive safety and efficacy results three months post-dosing in its SLAB trial for the SIRT6 centenarian gene therapy in aged dogs, with no adverse events observed and previously reported improvements maintained. The trial, which is ongoing and expected to conclude in July 2026, is providing early evidence of the therapy's durable effects, contrasting with expected age-related decline in control animals. Further mechanistic insights are anticipated fr</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/total-voting-rights-828</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/total-voting-rights-828</guid>
<pubDate>Tue, 31 Mar 2026 06:00:00 GMT</pubDate>
<description>Genflow Biosciences plc has announced that as of 31 March 2026, its total issued share capital comprises 535,653,205 ordinary shares, with no shares held in treasury, resulting in a total of 535,653,205 voting rights. This figure will serve as the denominator for shareholders to determine notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Issue of Equity & PDMR Notifications</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-issue-of-equity-and-pdmr-notifications-6</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-issue-of-equity-and-pdmr-notifications-6</guid>
<pubDate>Thu, 05 Mar 2026 12:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Result of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-result-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-result-of-gm</guid>
<pubDate>Mon, 02 Mar 2026 12:55:00 GMT</pubDate>
<description>Results of General Meeting LONDON, UK / ACCESS Newswire / March 2, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") a leading European-based biotechnology company focusing on longevity, is pleased to announce that ...</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Receipt of First Tranche of Grant</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-receipt-of-first-tranche-of-grant</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-receipt-of-first-tranche-of-grant</guid>
<pubDate>Mon, 02 Mar 2026 07:05:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Preliminary Interim Results From Dog Study</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-preliminary-interim-results-from-dog-study</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-preliminary-interim-results-from-dog-study</guid>
<pubDate>Thu, 12 Feb 2026 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Notice of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/notice-of-gm-19</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/notice-of-gm-19</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc is considering a potential equity raise through private placements, seeking shareholder approval at a general meeting on March 2, 2026, to issue up to 188,947,368 new ordinary shares, approximately 38% of its current issued share capital. This would involve dis-applying pre-emption rights to facilitate the swift conclusion of the raise, the proceeds of which would fund the MASH program's IND-enabling stage, animal health payments, glaucoma proof-of-concept studies, and pa</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Notice of GM</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-notice-of-gm</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-notice-of-gm</guid>
<pubDate>Wed, 11 Feb 2026 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Holding(s) in Company</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-holding-132500387</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-holding-132500387</guid>
<pubDate>Fri, 30 Jan 2026 13:25:00 GMT</pubDate>
<description>LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BP2C3V08 Issuer Name GENFLOW BIOSCIENCES PLC UK or Non-UK Issuer UK 2. Reason for Notification An acquisition or disposal ...</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/holdings-in-company-334</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/holdings-in-company-334</guid>
<pubDate>Fri, 30 Jan 2026 12:29:00 GMT</pubDate>
<description>Jonathan Mark Swann has increased his holding in Genflow Biosciences PLC, crossing a notification threshold on January 23, 2026. His total voting rights now stand at 12.13%, representing 59,861,278 shares, up from a previous notification of 11.32%. This acquisition of voting rights is the sole reason for the notification, with no financial instruments involved.
Disclaimer*</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Administrative Approval of Grant & 2026 Priorities</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-administrative-approval-of-grant-and-2026-priorities</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-administrative-approval-of-grant-and-2026-priorities</guid>
<pubDate>Wed, 28 Jan 2026 07:00:00 GMT</pubDate>
<description>LONDON, UK / ACCESS Newswire / January 28, 2026 /THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK ...</description>
</item>
<item>
<title>Genflow Biosciences PLC Announces Directorate Change</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-directorate-change</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-biosciences-plc-announces-directorate-change</guid>
<pubDate>Mon, 19 Jan 2026 07:20:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Directorate change</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/directorate-change-227</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/directorate-change-227</guid>
<pubDate>Mon, 19 Jan 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has appointed Gad Berdugo as its new Independent Non-Executive Chairman to drive corporate and R&D expansion, leveraging his extensive experience in biotechnology, capital markets, and company building, particularly in RNA-based therapeutics and LNP delivery. Mr. Berdugo, currently Managing Partner of Explorium Capital LLC, brings a strong track record from previous roles including CEO of EpiVax Oncology and Chief Business Officer at Editas Medicine. This strategic appoin</description>
</item>
<item>
<title>Review of 2025</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/review-of-2025</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/review-of-2025</guid>
<pubDate>Thu, 08 Jan 2026 07:00:00 GMT</pubDate>
<description>Genflow Biosciences PLC reported on its 2025 progress, highlighting advancements in its canine aging study (GF-1004) with no adverse events observed during the dosing phase and an initial efficacy readout expected in Q1 2026. The company also made strides with its MASH program (GF-1002), repositioning it for advanced fibrosis and generating preclinical data on HCC prevention, while exploring mRNA/LNP delivery. Genflow expanded into ophthalmology with a SIRT6-based gene therapy for glaucoma, targ</description>
</item>
<item>
<title>Completion of Dosing Phase of Canine Gene Therapy</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/completion-of-dosing-phase-of-canine-gene-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/completion-of-dosing-phase-of-canine-gene-therapy</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc has successfully completed the dosing phase of its canine gene therapy trial for its investigational SIRT6-based therapy, reporting no adverse events during administration, which demonstrates a strong safety and tolerability profile. The company anticipates a first efficacy read in mid-to-late January 2026, with a second assessment planned for June-July 2026, after which Genflow intends to resume discussions regarding potential early-stage licensing opportunities with ani</description>
</item>
<item>
<title>Genflow Completes Dosing Phase of Canine Gene Therapy Trial</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-completes-dosing-phase-of-canine-gene-therapy-trial</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-completes-dosing-phase-of-canine-gene-therapy-trial</guid>
<pubDate>Tue, 16 Dec 2025 07:00:00 GMT</pubDate>
<description>THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ...</description>
</item>
<item>
<title>Genflow to Attend Healthcare Conference</title>
<link>https://6ix.com/company/genflow-biosciences-plc/news/genflow-to-attend-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/genflow-biosciences-plc/news/genflow-to-attend-healthcare-conference</guid>
<pubDate>Thu, 11 Dec 2025 07:00:00 GMT</pubDate>
<description>Genflow Biosciences Plc announced its attendance at the 44th Annual J.P. Morgan Healthcare Conference from January 12-15, 2026, in San Francisco, aiming to engage with potential partners and investors regarding its longevity gene-therapy pipeline, specifically its SIRT6 longevity pathway focus and lipid nanoparticle delivery for mRNA SIRT6 therapeutics. The company's CEO highlighted the opportunity for strategic partnerships in the longevity space.
Disclaimer*</description>
</item>
</channel>
</rss>